乳腺癌筛查和早期诊断的血液生物学标志物

doi:10.3760/cma.j.cn371439-20200629-00021

摘要/Abstract

摘要：

乳腺癌筛查是对无症状人群采取经济、有效和简便的检查措施进行筛查,实现早发现、早诊断和早治疗的目标。现有的筛查方法如乳腺X线和超声检查对早期病变敏感性较差,无法评估无症状人群乳腺癌发病风险。乳腺癌易感基因、DNA甲基化、微小RNA和循环肿瘤细胞作为乳腺癌筛查和早期诊断的血液生物学标志物,可以识别乳腺癌高危人群,提高乳腺癌的早期诊断率。

关键词: 乳腺肿瘤, 基因检测, 早期诊断, 生物学标志物

Abstract:

Breast cancer screening is an economical, effective, and simple screening measure for asymptomatic people to achieve the goals of early detection, early diagnosis and early treatment. Existing screening methods are mainly based on breast cancer X-rays and ultrasound, which are less sensitive to early lesions and cannot assess the risk of breast cancer in asymptomatic people. Breast cancer susceptibility genes, DNA methylation, microRNAs and circulating tumor cells, as blood biomarkers for breast cancer screening and early diagnosis, can identify high-risk breast cancer populations and improve the early diagnosis rate of breast cancer.

Key words: Breast neoplasms, Genetic testing, Early diagnosis, Biomarker

黎立喜, 马飞. 乳腺癌筛查和早期诊断的血液生物学标志物[J]. 国际肿瘤学杂志, 2021, 48(2): 109-112.

Li Lixi, Ma Fei. Blood biomarkers for breast cancer screening and early diagnosis[J]. Journal of International Oncology, 2021, 48(2): 109-112.

参考文献 36

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492 pmid: 30207593
[2]	Li X, Xu Y, Zhang L. Serum CA153 as biomarker for cancer and noncancer diseases[J]. Prog Mol Biol Transl Sci, 2019,162:265-276. DOI: 10.1016/bs.pmbts.2019.01.005. doi: 10.1016/bs.pmbts.2019.01.005 pmid: 30905456
[3]	Rebbeck TR, Mitra N, Wan F, et al. Association of type and location of brca1 and brca2 mutations with risk of breast and ovarian cancer[J]. JAMA, 2015,313(13):1347-1361. DOI: 10.1001/jama.2014.5985. doi: 10.1001/jama.2014.5985 pmid: 25849179
[4]	Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large united states sample[J]. J Clin Oncol, 2006,24(6):863-871. DOI: 10.1200/jco.2005.03.6772. doi: 10.1200/JCO.2005.03.6772 pmid: 16484695
[5]	Sun J, Meng H, Yao L, et al. Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients[J]. Clin Cancer Res, 2017,23(20):6113-6119. DOI: 10.1158/1078-0432.CCR-16-3227. pmid: 28724667
[6]	Buys SS, Sandbach JF, Gammon A, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes[J]. Cancer, 2017,123(10):1721-1730. DOI: 10.1002/cncr.30498. pmid: 28085182
[7]	Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer[J]. J Clin Oncol, 2016,34(13):1460-1468. DOI: 10.1200/JCO.2015.65.0747. doi: 10.1200/JCO.2015.65.0747 pmid: 26976419
[8]	Yang X, Wu J, Lu J, et al. Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a chinese population by next-generation sequencing[J]. PLoS One, 2015,10(4):e0125571. DOI: 10.1371/journal.pone.0125571. doi: 10.1371/journal.pone.0125571 pmid: 25927356
[9]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019,29(8):609-679. DOI: 10.19401/j.cnki.1007-3639.2019.08.009.
[10]	Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial[J]. Lancet Oncol, 2015,16(1):67-75. DOI: 10.1016/s1470-2045(14)71171-4. doi: 10.1016/S1470-2045(14)71171-4 pmid: 25497694
[11]	Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-Ⅱ): an international, double-blind, randomised placebo-controlled trial[J]. Lancet, 2014,383(9922):1041-1048. DOI: 10.1016/s0140-6736(13)62292-8. doi: 10.1016/S0140-6736(13)62292-8 pmid: 24333009
[12]	Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer[J]. Cochrane Database Syst Rev, 2018,4(4):CD002748. DOI: 10.1002/14651858.CD002748.pub4.
[13]	Heemskerk-Gerritsen BAM, Jager A, Koppert LB, et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers[J]. Breast Cancer Res Treat, 2019,177(3):723-733. DOI: 10.1007/s10549-019-05345-2. doi: 10.1007/s10549-019-05345-2 pmid: 31302855
[14]	Brennan K, Garcia-Closas M, Orr N, et al. Intragenic ATM methy-lation in peripheral blood DNA as a biomarker of breast cancer risk[J]. Cancer Res, 2012,72(9):2304-2313. DOI: 10.1158/0008-5472.can-11-3157. doi: 10.1158/0008-5472.CAN-11-3157 pmid: 22374981
[15]	Chen J, Haanpää MK, Gruber JJ, et al. High-resolution bisulfite-sequencing of peripheral blood DNA methylation in early-onset and familial risk breast cancer patients[J]. Clin Cancer Res, 2019,25(17):5301-5314. DOI: 10.1158/1078-0432.ccr-18-2423. pmid: 31175093
[16]	Bosviel R, Garcia S, Lavediaux G, et al. BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls[J]. Cancer Epidemiol, 2012,36(3):e177-e182. DOI: 10.1016/j.canep.2012.02.001. doi: 10.1016/j.canep.2012.02.001
[17]	Tang Q, Holland-Letz T, Slynko A, et al. DNA methylation array analysis identifies breast cancer associated RPTOR, MGRN1 and RAPSN hypomethylation in peripheral blood DNA[J]. Oncotarget, 2016,7(39):64191-64202. DOI: 10.18632/oncotarget.11640. doi: 10.18632/oncotarget.11640 pmid: 27577081
[18]	Yang R, Pfütze K, Zucknick M, et al. DNA methylation array analyses identified breast cancer-associated HYAL2 methylation in peripheral blood[J]. Int J Cancer, 2015,136(8):1845-1855. DOI: 10.1002/ijc.29205. doi: 10.1002/ijc.29205 pmid: 25213452
[19]	Yang R, Stöcker S, Schott S, et al. The association between breast cancer and S100P methylation in peripheral blood by multicenter case-control studies[J]. Carcinogenesis, 2017,38(3):312-320. DOI: 10.1093/carcin/bgx004. doi: 10.1093/carcin/bgx004 pmid: 28426874
[20]	Parashar S, Cheishvili D, Mahmood N, et al. DNA methylation signatures of breast cancer in peripheral T-cells[J]. BMC Cancer, 2018,18(1):574. DOI: 10.1186/s12885-018-4482-7. pmid: 29776342
[21]	Shan M, Yin H, Li J, et al. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer[J]. Oncotarget, 2016,7(14):18485-18494. DOI: 10.18632/oncotarget.7608. doi: 10.18632/oncotarget.7608 pmid: 26918343
[22]	Cao X, Tang Q, Holland-Letz T, et al. Evaluation of promoter methy-lation of RASSF1A and ATM in peripheral blood of breast cancer patients and healthy control individuals[J]. Int J Mol Sci, 2018,19(3):900. DOI: 10.3390/ijms19030900. doi: 10.3390/ijms19030900
[23]	Bodelon C, Ambatipudi S, Dugué PA, et al. Blood DNA methylation and breast cancer risk: a meta-analysis of four prospective cohort studies[J]. Breast Cancer Res, 2019,21(1):62. DOI: 10.1186/s13058-019-1145-9. pmid: 31101124
[24]	Bind MA, Zanobetti A, Gasparrini A, et al. Effects of temperature and relative humidity on DNA methylation[J]. Epidemiology, 2014,25(4):561-569. DOI: 10.1097/ede.0000000000000120. doi: 10.1097/EDE.0000000000000120 pmid: 24809956
[25]	Zhang FF, Cardarelli R, Carroll J, et al. Significant differences in global genomic DNA methylation by gender and race/ethnicity in peripheral blood[J]. Epigenetics, 2011,6(5):623-629. DOI: 10.4161/epi.6.5.15335. pmid: 21739720
[26]	Lal A, Ramazzotti D, Weng Z, et al. Comprehensive genomic cha-racterization of breast tumors with BRCA1 and BRCA2 mutations[J]. BMC Medical Genomics, 2019,12(1):84. DOI: 10.1186/s12920-019-0545-0. doi: 10.1186/s12920-019-0545-0 pmid: 31182087
[27]	Xu Z, Sandler DP, Taylor JA. Blood DNA methylation and breast cancer: a prospective case-cohort analysis in the sister study[J]. J Natl Cancer Inst, 2020,112(1):87-94. DOI: 10.1093/jnci/djz065. doi: 10.1093/jnci/djz065 pmid: 30989176
[28]	Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017,16(3):203-222. DOI: 10.1038/nrd.2016.246. doi: 10.1038/nrd.2016.246 pmid: 28209991
[29]	Farina NH, Ramsey JE, Cuke ME, et al. Development of a predictive mirna signature for breast cancer risk among high-risk women[J]. Oncotarget, 2017,8(68):112170-112183. DOI: 10.18632/oncotarget.22750. doi: 10.18632/oncotarget.22750 pmid: 29348816
[30]	Mishra S, Srivastava AK, Suman S, et al. Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer[J]. Cancer Lett, 2015,369(1):67-75. DOI: 10.1016/j.canlet.2015.07.045. doi: 10.1016/j.canlet.2015.07.045
[31]	Zhang K, Wang YW, Wang YY, et al. Identification of microRNA biomarkers in the blood of breast cancer patients based on microNRA profiling[J]. Gene, 2017,619:10-20. DOI: 10.1016/j.gene.2017.03.038. pmid: 28359916
[32]	Shimomura A, Shiino S, Kawauchi J, et al. Novel combination of serum microrna for detecting breast cancer in the early stage[J]. Cancer Sci, 2016,107(3):326-334. DOI: 10.1111/cas.12880. doi: 10.1111/cas.12880 pmid: 26749252
[33]	Bidard FC, Michiels S, Riethdorf S, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis[J]. J Natl Cancer Inst, 2018,110(6):560-567. DOI: 10.1093/jnci/djy018. doi: 10.1093/jnci/djy018 pmid: 29659933
[34]	Rack B, Schindlbeck C, Jückstock J, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients[J]. J Natl Cancer Inst, 2014,106(5):dju066. DOI: 10.1093/jnci/dju066. doi: 10.1093/jnci/dju066 pmid: 24832787
[35]	Franken B, de Groot MR, Mastboom WJ, et al. Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer[J]. Breast Cancer Res, 2012,14(5):R133. DOI: 10.1186/bcr3333. pmid: 23088337
[36]	Zhang Y, Lv Y, Niu Y, et al. Role of circulating tumor cell (CTC) monitoring in evaluating prognosis of triple-negative breast cancer patients in China[J]. Med Sci Monit, 2017,23:3071-3079. DOI: 10.12659/msm.902637. doi: 10.12659/msm.902637 pmid: 28643770